Imfinzi

(Durvalumab)

ApprovedMonoclonal antibody

Durvalumab is used to treat certain types of lung cancer and bladder cancer by helping the immune system recognize and attack cancer cells.[2] Imfinzi is currently approved and in use across 130 indications[4].[1]

Imfinzi is one of 1367 small molecule programs targeting Prostate Cancer. It is currently in Approved.

130

Indications

662

Total Trials

Active Trials

1,366

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Prostate CancerCompleted

Gastric CancerRecruiting

Solid TumorsCompleted

Urothelial CarcinomaTerminated

Esophageal CancerActive, not recruiting

MesotheliomaCompleted

AdenocarcinomaWithdrawn

Chronic Lymphocytic LeukemiaCompleted

Lung Non-Small Cell CarcinomaRecruiting

ImmunotherapyTerminated

Prostate CancerPhase 2

Completed

Gastric CancerPhase 2

Recruiting

Solid TumorsPhase 2

Completed

Urothelial CarcinomaPhase 2

Terminated

Esophageal CancerPhase 2

Active, not recruiting

MesotheliomaPhase 3

Completed

AdenocarcinomaPhase 2

Withdrawn

Chronic Lymphocytic LeukemiaPhase 2

Completed

Lung Non-Small Cell CarcinomaPhase 3

Recruiting

ImmunotherapyPhase 2

Terminated

Showing 10 of 130 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Approved

24 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Spravato

WWim Janssens

Preclinical

2 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Tricor

JJagotec

Preclinical

1 8

Acupan

YYonsei University

Preclinical

1 9

Chantix

PPrism Pharmaceuticals

Preclinical

1 10

Nubain

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Locally Advanced

NCT03589547

Phase 3Active, not recruiting

Lung Cancer

NCT03703297

Phase 2Active, not recruiting

Advanced NSCLC

NCT05000710

Phase 1/2Active, not recruiting

Biliary Tract Cancer

NCT04781192

Phase 2Recruiting

Biliary Tract Cancer

NCT05222971

Phase 2Recruiting

Bladder Cancer

NCT06263153

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer24 trials

Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

Withdrawn·EEmory University·Phase 2·NCT04262869

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02983578·39 enrolled

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

Active, not recruiting·YYonsei University·Phase 2·NCT05206812·25 enrolled

Show 21 more trials

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04380636·870 enrolled

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Completed·LLudwig Institute for Cancer Research·Phase 1/2·NCT02898116·2 enrolled

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03801902·26 enrolled

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT04513925·829 enrolled

Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Withdrawn·EETOP IBCSG Partners Foundation·Phase 2·NCT05718297

The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

Not yet recruiting·MMontefiore Medical Center·Phase 2·NCT07146230·52 enrolled

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04026412·925 enrolled

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT03794544·84 enrolled

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Completed·—·Phase 2·NCT02879617·47 enrolled

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Active, not recruiting·UUniversity of Birmingham·Phase 2·NCT02664935·423 enrolled

Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

Unknown status·PPeking Union Medical College Hospital·Phase 1/2·NCT04646837·20 enrolled

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

Completed·WWeill Medical College of Cornell University·Phase 2·NCT02904954·60 enrolled

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Terminated·MMayo Clinic·Phase 1·NCT05443971·4 enrolled

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Not yet recruiting·—·Phase 2·NCT07288034·535 enrolled

A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06606847·30 enrolled

Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT04889066

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04716946·13 enrolled

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05221840·1,051 enrolled

Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer

Terminated·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT03030131·50 enrolled

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT05848843

Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Unknown status·HHui Bu·Phase 4·NCT04356222·30 enrolled

Small Cell Lung Cancer9 trials

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Suspended·HHirva Mamdani·Phase 2·NCT05903092·84 enrolled

Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer

Unknown status·—·Phase 2·NCT05034133·20 enrolled

Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

Recruiting·UUNICANCER·Phase 2·NCT05617963·100 enrolled

Show 6 more trials

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Recruiting·UUniversity of Chicago·Phase 2·NCT05068232·49 enrolled

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04728230·63 enrolled

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT04397003·6 enrolled

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Recruiting·SSWOG Cancer Research Network·Phase 2·NCT06769126·900 enrolled

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Active, not recruiting·SSwiss Cancer Institute·Phase 2·NCT04472949·46 enrolled

REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Completed· AstraZeneca logo

AstraZeneca··NCT06826677·71 enrolled

Lung Cancer8 trials

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT05911308·1 enrolled

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Active, not recruiting· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT01993810·330 enrolled

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Completed·SSWOG Cancer Research Network·Phase 2/3·NCT02766335·116 enrolled

Show 5 more trials

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03421353·76 enrolled

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Recruiting·—·Phase 1/2·NCT05886439·60 enrolled

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT03703297·730 enrolled

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)

Enrolling by invitation·UUniversity of Cologne·Phase 2·NCT06419179·29 enrolled

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Terminated·UUniversity of Wisconsin, Madison·Phase 1·NCT03275597·17 enrolled

Hepatocellular Carcinoma8 trials

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Recruiting·AAnwaar Saeed·Phase 2·NCT06698250·40 enrolled

A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma

Withdrawn·WWeill Medical College of Cornell University·Phase 2·NCT06994299

SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma

Unknown status·TThe University of Hong Kong·Phase 2·NCT04913480·37 enrolled

Show 5 more trials

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Withdrawn·—·Phase 1/2·NCT06608940

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03638141·21 enrolled

A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

Terminated·AAVEO Pharmaceuticals, Inc.·Phase 1/2·NCT03970616·27 enrolled

Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma

Completed·SSun Yat-sen University·Phase 2·NCT04945720·30 enrolled

Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma

Recruiting·ZZhiyong Huang·Phase 1·NCT06470256·50 enrolled

Bladder Cancer7 trials

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Recruiting·YYuanquan Yang·Phase 2·NCT06263153·24 enrolled

Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)

Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT03534492·29 enrolled

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

Recruiting·UUniversity College, London·Phase 1/2·NCT04106115·64 enrolled

Show 4 more trials

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Unknown status·HHellenic GenitoUrinary Cancer Group·Phase 2·NCT03759496·39 enrolled

TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer

Withdrawn·—·Phase 1·NCT04073160

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT03601455·13 enrolled

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04216290·95 enrolled

91 more indications

Pancreatic Cancer6 trials

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Unknown status·—·Phase 1/2·NCT05327582·65 enrolled

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02734160·37 enrolled

NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

Active, not recruiting·AAustralasian Gastro-Intestinal Trials Group·Phase 2·NCT06094140·20 enrolled

Show 3 more trials

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT03245541·18 enrolled

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02311361·65 enrolled

Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

Completed·GGWT-TUD GmbH·Phase 1/2·NCT04257448·75 enrolled

Chemoradiotherapy4 trials

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Recruiting·YYonsei University·Phase 1/2·NCT03694236·39 enrolled

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Recruiting·MMaximilian Diehn·Phase 3·NCT04585490·48 enrolled

Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

Terminated·TThe Netherlands Cancer Institute·Phase 1·NCT04287894·18 enrolled

Show 1 more trial

Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.

Completed·FFundación GECP··NCT04285866·245 enrolled

Durvalumab4 trials

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04495179·30 enrolled

Diadem to Investigate the Activity and Safety of Durvalumab

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT04115111·57 enrolled

To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

Unknown status·SShanghai Chest Hospital·N/A·NCT04985851·90 enrolled

Show 1 more trial

Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN

Active, not recruiting·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 2·NCT03726775·61 enrolled

Biliary Tract Cancer4 trials

Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy

Recruiting·—·Phase 2·NCT05222971·62 enrolled

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Not yet recruiting·WWashington University School of Medicine·Phase 1·NCT07107750·48 enrolled

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Unknown status·—·Phase 1/2·NCT06255262·30 enrolled

Show 1 more trial

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

Active, not recruiting·UUniversity of Kansas Medical Center·Phase 1/2·NCT04781192·40 enrolled

Urothelial Carcinoma4 trials

Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

Active, not recruiting·UUniversity of Utah·Phase 1·NCT05154994·9 enrolled

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Terminated·LLatin American Cooperative Oncology Group·Phase 2·NCT04579133·140 enrolled

NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma

Active, not recruiting·AAssociation Pour La Recherche des Thérapeutiques Innovantes en Cancérologie·Phase 1/2·NCT03549715·121 enrolled

Show 1 more trial

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Terminated·—·Phase 2·NCT04322643·4 enrolled

Chemotherapy4 trials

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Recruiting·AAHS Cancer Control Alberta·Phase 2·NCT05451043·62 enrolled

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Withdrawn·SShirish M Gadgeel·Phase 2·NCT04470674

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT03611556·213 enrolled

Show 1 more trial

Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC

Terminated· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT04765709·10 enrolled

Colorectal Cancer4 trials

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03122509·25 enrolled

Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer

Completed·CCanadian Cancer Trials Group·Phase 2·NCT02870920·180 enrolled

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT03206073·34 enrolled

Show 1 more trial

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02754856·24 enrolled

Breast Cancer4 trials

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT04538742·245 enrolled

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

Completed·GGrand Hôpital de Charleroi·Phase 1/2·NCT03356860·57 enrolled

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

Completed·KKing Faisal Specialist Hospital & Research Center·Phase 1/2·NCT02628132·22 enrolled

Show 1 more trial

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Completed·CCanadian Cancer Trials Group·Phase 1·NCT02649686·15 enrolled

Esophageal Cancer4 trials

A Study of Durvalumab (MEDI4736) in Esophageal Cancer

Completed·SShadia Jalal, MD·Phase 2·NCT02639065·39 enrolled

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Recruiting·UUniversity of California, Irvine·Phase 1·NCT05733689·20 enrolled

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Completed·LLudwig Institute for Cancer Research·Phase 1/2·NCT02735239·73 enrolled

Show 1 more trial

Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab

Active, not recruiting·—·Phase 2·NCT03653052·18 enrolled

Locally Advanced3 trials

Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC

Completed·UUlrich Keilholz·Phase 2·NCT03624231·18 enrolled

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung

Active, not recruiting·—·Phase 2·NCT03589547·11 enrolled

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT04416633·100 enrolled

Ovarian Cancer3 trials

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Completed·AAmy Tiersten·Phase 1·NCT03430518·9 enrolled

TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02764333·29 enrolled

NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study

Not yet recruiting·BBritish Columbia Cancer Agency·Phase 2·NCT06650709·40 enrolled

Intrahepatic Cholangiocarcinoma3 trials

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Withdrawn·GGeorgetown University·Phase 2·NCT06017297

Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

Recruiting·WWest China Hospital·Phase 2·NCT06859684·25 enrolled

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Recruiting·MMayo Clinic·Phase 1·NCT06058663·16 enrolled

Triple-Negative Breast Cancer3 trials

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

Recruiting·QQueen Mary University of London·Phase 2·NCT06954480·140 enrolled

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05629585·1,174 enrolled

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1/2·NCT06508216·50 enrolled

Prostate Cancer3 trials

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Withdrawn·UUniversity of Washington·Phase 2·NCT02966587

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03204812·31 enrolled

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04089553·59 enrolled

Squamous Cell Carcinoma3 trials

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03381183·19 enrolled

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

Withdrawn·UUniversity Health Network, Toronto·Phase 1·NCT02993991

Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma

Completed·UUniversity of Colorado, Denver·Phase 1·NCT03635164·21 enrolled

Glioblastoma2 trials

A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma

Completed·IInstitut Claudius Regaud·Phase 1/2·NCT02866747·108 enrolled

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

Completed·LLudwig Institute for Cancer Research·Phase 2·NCT02336165·159 enrolled

Liver Cancer2 trials

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Recruiting·EEmory University·Phase 2·NCT07174570·39 enrolled

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Active, not recruiting·—·Phase 1·NCT04605731·25 enrolled

Advanced Solid Tumors2 trials

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02658214·32 enrolled

Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02900157·42 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT02997332·14 enrolled

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Terminated·UUniversity of Washington·Phase 1/2·NCT03522584·6 enrolled

Solid Tumors2 trials

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT02556463·53 enrolled

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT02671435·383 enrolled

Papilloma2 trials

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Terminated·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT03618134·19 enrolled

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT03162224·35 enrolled

Tremelimumab2 trials

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Completed·LLudwig Institute for Cancer Research·Phase 1/2·NCT02643303·58 enrolled

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Completed·CCatherine Shu·Phase 1·NCT03085849·2 enrolled

Elderly Patients2 trials

A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT03975114·460 enrolled

Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC

Terminated·RRush University Medical Center·Phase 2·NCT04441138·10 enrolled

Pancreatic Adenocarcinoma2 trials

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Terminated·GGeorgetown University·Phase 1/2·NCT03376659·8 enrolled

Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Completed·CCanadian Cancer Trials Group·Phase 2·NCT02879318·180 enrolled

Patients With Solid Tumors2 trials

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Completed·SSyndax Pharmaceuticals·Phase 1·NCT03238027·45 enrolled

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Recruiting·RRahul Aggarwal·Phase 2·NCT03682289·89 enrolled

Oropharynx Cancer2 trials

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04001413

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Terminated·WWake Forest University Health Sciences·Phase 1·NCT02827838·17 enrolled

Metastatic Colorectal Cancer2 trials

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

Terminated·UUniversity of Iowa·Phase 1·NCT04108481·5 enrolled

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

Completed·—·Phase 1·NCT03005002·9 enrolled

Patients With Advanced Solid Tumors1 trial

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03509012·105 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma

Completed·PPeking Union Medical College Hospital·Phase 2·NCT04568200·60 enrolled

Cutaneous T-cell lymphoma1 trial

Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT03235869

Intratumoral Injection1 trial

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Completed· Moderna logo

Moderna·Phase 1·NCT03739931·134 enrolled

Multiple Myeloma1 trial

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02616640·114 enrolled

Uveal Melanoma1 trial

Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma

Withdrawn·GGrupo Español Multidisciplinar de Melanoma·Phase 2·NCT04184518

Neoadjuvant1 trial

Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Unknown status·JJuan LI, MD·Phase 1·NCT05157542·9 enrolled

Cervical Cancer1 trial

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03830866·770 enrolled

Treatment1 trial

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT04637594·3 enrolled

Renal Cell Carcinoma1 trial

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

Completed·MMoshe Ornstein·Phase 1·NCT02762006·29 enrolled

Thyroid Carcinoma1 trial

Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

Terminated·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT03753919·79 enrolled

Advanced Solid Malignancies1 trial

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02740985·313 enrolled

Radiotherapy1 trial

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03410615·129 enrolled

Mesothelioma1 trial

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

Completed·PPrECOG, LLC.·Phase 2·NCT02899195·55 enrolled

Thyroid Cancer1 trial

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03122496·13 enrolled

Lymphoma1 trial

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Recruiting·UUniversity of Virginia·Phase 1/2·NCT03161223·148 enrolled

Refractory Solid Tumors1 trial

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02403271·124 enrolled

Kidney Cancer1 trial

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Active, not recruiting·—·Phase 1/2·NCT03308396·57 enrolled

Second-line Therapy1 trial

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Recruiting·RReplimune Inc.·Phase 2·NCT05733598·60 enrolled

Myelodysplastic Syndromes1 trial

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02775903·213 enrolled

Solid Malignancies1 trial

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Active, not recruiting·CCanadian Cancer Trials Group·Phase 1·NCT02537418·153 enrolled

Oligometastatic1 trial

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Recruiting·UUniversität des Saarlandes·Phase 2·NCT06223711·43 enrolled

Gynecologic Cancer1 trial

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Terminated·—·Phase 1·NCT03277482·16 enrolled

Small Cell Carcinoma1 trial

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA

Recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT06464068·66 enrolled

Chronic Lymphocytic Leukemia1 trial

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02733042·106 enrolled

Neoadjuvant Therapy1 trial

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Withdrawn·UUniversity of Colorado, Denver·Phase 2·NCT03038477

Fallopian Tube Cancer1 trial

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

Unknown status·BBritish Columbia Cancer Agency·Phase 1·NCT03283943·22 enrolled

Toxicity1 trial

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown status·CCCTU- Cancer Theme··NCT04107168·1,800 enrolled

Unresectable1 trial

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unknown status·SShandong Cancer Hospital and Institute·Phase 2·NCT04982549·35 enrolled

Metastatic Head and Neck Cancer1 trial

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Completed·MMassachusetts General Hospital·Phase 1·NCT03019003·13 enrolled

Hepatocellular Cancer1 trial

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

Not yet recruiting·AAmit Mahipal·Phase 2·NCT07226063·16 enrolled

Rectal Cancer1 trial

A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer

Unknown status·LLiz-Anne Lewsley·Phase 2·NCT04621370·48 enrolled

Advanced NSCLC1 trial

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

Active, not recruiting·SSheba Medical Center·Phase 2·NCT05000710·29 enrolled

Neoadjuvant Treatment1 trial

Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC

Unknown status·OOttawa Hospital Research Institute·Phase 2·NCT04543110·16 enrolled

Essential Thrombocythemia1 trial

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Withdrawn·NNorthwestern University·Phase 1·NCT02871323

Stereotactic Body Radiation Therapy1 trial

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03452332·20 enrolled

Chronic HBV Infection1 trial

Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

Withdrawn·AArbutus Biopharma Corporation·Phase 2·NCT06245291

Proton Radiotherapy1 trial

Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

Recruiting·—·Phase 2·NCT06999694·45 enrolled

Malignant Glioma1 trial

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Completed·NNorthwestern University·Phase 2·NCT02794883·36 enrolled

Immunotherapy1 trial

Single cEll pRofiling PErsistaNce To ImmuNothErapy

Recruiting·VVall d'Hebron Institute of Oncology·Phase 2·NCT06680739·60 enrolled

Adenocarcinoma1 trial

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Active, not recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03959293·107 enrolled

Relapsed/Refractory B-cell Malignancies1 trial

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03310619·62 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of CRT, Durvalumab and Surgery for SST

Not yet recruiting·NNational Cancer Center Hospital East·Phase 3·NCT04465968·84 enrolled

Biomarker1 trial

Biomarker-based Study in R/M SCCHN

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03088059·340 enrolled

Advanced Rare Tumours1 trial

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Completed·CCanadian Cancer Trials Group·Phase 2·NCT02879162·140 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

Recruiting·—·Phase 1/2·NCT05927142·43 enrolled

Pilot Study1 trial

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Completed·MMary Crowley Medical Research Center·Phase 2·NCT02725489·13 enrolled

Metastatic Colon Cancer1 trial

Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03428126·29 enrolled

Efficacy1 trial

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02815995·57 enrolled

Malignancies1 trial

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Completed·LLudwig Institute for Cancer Research·Phase 1/2·NCT02963831·67 enrolled

Gastroesophageal Junction Cancer1 trial

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04592913·957 enrolled

Plasmacytoma1 trial

A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma

Withdrawn·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03196401

Metastatic Cancer1 trial

A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1/2·NCT03212469·54 enrolled

Endometrial Carcinoma1 trial

Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma

Unknown status·SShanghai First Maternity and Infant Hospital·N/A·NCT04444193·20 enrolled

ESS1 trial

Himalaya Early Access Program

Approved for marketing· AstraZeneca logo

AstraZeneca··NCT05345678

Hormone Therapy1 trial

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Recruiting·NNational Taiwan University Hospital·Phase 2·NCT05720260·42 enrolled

Resectable NSCLC1 trial

Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC

Terminated·—·Phase 1·NCT03818776·7 enrolled

Adjuvant1 trial

Renal Adjuvant MultiPle Arm Randomised Trial

Recruiting·UUniversity College, London·Phase 3·NCT03288532·1,750 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC

Completed·SSeoul National University Hospital·Phase 1/2·NCT04124991·24 enrolled

Fibrolamellar Carcinoma1 trial

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT06027086·27 enrolled

Non-squamous NSCLC1 trial

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT04686305·244 enrolled

Diffuse Large B-Cell Lymphoma1 trial

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03003520·46 enrolled

Microbiota1 trial

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

Not yet recruiting·FFundación GECP·Phase 2·NCT07247786·68 enrolled

Nasopharyngeal Carcinoma1 trial

Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

Unknown status·TThe University of Hong Kong·Phase 2·NCT04447612·118 enrolled

Regulatory

FDA Approval Timeline[5]

May 1, 2017

IMFINZI

NDA BLA761069

May 1, 2017

IMFINZI

BLA BLA761069

May 1, 2017

Imfinzi

BLA 761069

Feb 16, 2018

IMFINZI

NDA BLA761069

Jul 19, 2019

IMFINZI

NDA BLA761069

Aug 26, 2019

IMFINZI

NDA BLA761069

Mar 27, 2020

IMFINZI

NDA BLA761069

Jun 5, 2020

IMFINZI

NDA BLA761069

Nov 10, 2020

IMFINZI

NDA BLA761069

Nov 18, 2020

IMFINZI

NDA BLA761069

Nov 18, 2020

IMFINZI

NDA BLA761069

Nov 18, 2020

IMFINZI

NDA BLA761069

Feb 19, 2021

IMFINZI

NDA BLA761069

Jul 15, 2021

IMFINZI

NDA BLA761069

May 11, 2022

IMFINZI

NDA BLA761069

Sep 2, 2022

IMFINZI

NDA BLA761069

Oct 21, 2022

IMFINZI

NDA BLA761069

Nov 10, 2022

IMFINZI

NDA BLA761069

Jun 16, 2023

IMFINZI

NDA BLA761069

Dec 20, 2023

IMFINZI

NDA BLA761069

Apr 22, 2024

IMFINZI

NDA BLA761069

Jun 14, 2024

IMFINZI

NDA BLA761069

Jul 24, 2024

IMFINZI

NDA BLA761069

Aug 15, 2024

IMFINZI

NDA BLA761069

Dec 4, 2024

IMFINZI

NDA BLA761069

Feb 28, 2025

IMFINZI

NDA BLA761069

Mar 28, 2025

IMFINZI

NDA BLA761069

Nov 25, 2025

IMFINZI

NDA BLA761069

May 28, 2026

IMFINZI

NDA BLA761069

Aug 31, 2026

IMFINZI

NDA BLA761069

Sources

References

[1]
ClinicalTrials.gov — 662 trial records for Durvalumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Imfinzi drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Durvalumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Durvalumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA BLA761069). U.S. Food & Drug Administration.
[6]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Programmed Cell Death 1 Ligand 1 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: AstraZeneca